BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Should l Buy OCGN?
Source: Globenewswire
Investigations into Mergers: Brodsky & Smith is investigating several companies, including Carisma Therapeutics, Guaranty Bancshares, MRC Global, and Turnstone Biologics, for potential breaches of fiduciary duties by their boards during merger agreements, focusing on whether shareholders were treated fairly.
Legal Representation Offered: The law firm offers assistance to investors who may have concerns regarding these investigations, emphasizing that there is no cost or financial obligation for those who wish to discuss their cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCGN
Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.330
Low
7.00
Averages
7.67
High
8.00
Current: 1.330
Low
7.00
Averages
7.67
High
8.00
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ocugen Inc Announces $22.5 Million Stock Offering, Shares Drop 10.48%
- Stock Offering Impact: Ocugen announced a 15 million share offering at $1.50 per share, raising $22.5 million for general corporate purposes and capital spending, leading to investor concerns over dilution and a 10.48% drop in stock price.
- Market Reaction: The offering price below market expectations suggests institutional buyers may have demanded a discount, resetting market expectations for OCGN's near-term value and exacerbating downward pressure on the stock.
- Funding Need Risks: While the financing strengthens Ocugen's balance sheet and supports its gene therapy development, it also highlights the company's reliance on capital markets, increasing perceived risk in an already volatile biotech environment.
- Stock Performance: As of Wednesday, Ocugen shares fell to $1.49, reflecting investor concerns about future profitability, with dilution effects and ongoing cash needs driving significant declines in stock value.
See More
Ocugen (OCGN) Prices 15 Million Share Offering at $1.50, Raising $22.5 Million
- Funding Size: Ocugen announced the pricing of 15 million shares at $1.50 each, raising a total of $22.5 million, which will provide crucial financial support for the company's operations.
- Underwriter Background: The offering is led by RTW Investments and is expected to close around January 22, subject to customary conditions, indicating market confidence in Ocugen.
- Use of Proceeds: Ocugen stated that the net proceeds will be used for general corporate purposes, including capital expenditures, working capital, and general and administrative expenses, thereby enhancing the company's financial flexibility.
- Market Reaction: Following the announcement, Ocugen's stock price rose 8.08% in pre-market trading to $1.535 per share, reflecting investor optimism regarding the company's future prospects.
See More
Ocugen Prices 15 Million Share Offering at $1.50, Raising $22.5 Million
- Offering Size: Ocugen announced the pricing of 15 million shares at $1.50 each, raising a total of $22.5 million, which will be utilized for general corporate purposes and capital expenditures, thereby enhancing the company's financial flexibility.
- Underwriter Participation: The offering is led by RTW Investments with participation from new and existing investors, reflecting market confidence in Ocugen's gene therapy platform and potentially providing funding support for future R&D initiatives.
- Transaction Timeline: The offering is expected to close on or about January 22, 2026, subject to customary closing conditions, providing the company with a swift financing opportunity that could accelerate its research and development efforts.
- Registration Statement Background: This offering is conducted under Ocugen's S-3 registration statement filed on April 18, 2024, demonstrating the company's preparedness in compliance matters, ensuring investors can access relevant information and participate in the investment.
See More
Ocugen Inc Reports 46% Lesion Growth Reduction in Phase 2 Trial, Stock Rallies
- Clinical Trial Results: Ocugen's Phase 2 ArMaDa trial of OCU410 shows a 46% reduction in lesion growth compared to control, indicating significant disease-modifying potential that could position the therapy as an alternative to frequently injected treatments.
- Dose Effect Analysis: The medium dose of OCU410 demonstrated the strongest efficacy with a 54% reduction in lesion size, while the high dose showed a 36% decline, providing robust data support for future treatment options and likely attracting more investor interest.
- Future Development Plans: Ocugen is targeting a Phase 3 trial start in 2026 and plans to file a Biologics License Application in 2028, reflecting the company's confidence in its product pipeline, which may further drive stock price appreciation.
- Strong Market Performance: Ocugen shares are currently priced at $1.76, trading 17.7% above the 20-day simple moving average, indicating strong long-term market performance, with a 149.65% increase over the past 12 months, positioning closer to 52-week highs.
See More
Ocugen Reports Phase 2 Data for OCU410, 46% Lesion Reduction Achieved
- Clinical Trial Results: Preliminary data from Ocugen's Phase 2 trial for OCU410 shows a 46% reduction in lesion growth compared to the control group, indicating the gene therapy's potential efficacy in treating geographic atrophy.
- Dose Effect Analysis: The medium dose achieved a 54% reduction in lesion size, while the high dose showed a 36% reduction, suggesting varying efficacy across doses and potentially offering patients more flexible treatment options.
- Future Plans: Ocugen plans to report full Phase 2 trial data later this quarter and aims to initiate a Phase 3 trial in 2026, further advancing the clinical development of OCU410.
- Market Performance: Despite broader market gains, Ocugen's stock fell 9.08% to $1.71, reflecting a negative market reaction to its clinical data, which may impact future financing and market confidence.
See More
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
- Clinical Trial Progress: OS Therapies' Phase 2b trial of OST-HER2 revealed that immune blood biomarkers in the interferon gamma pathway effectively distinguish long-term from short-term survivors, bolstering their Biologics License Application (BLA) submission.
- Regulatory Approval Path: The company plans to submit its BLA to the FDA by Q2 2026, with regulatory approvals anticipated in the UK, US, and Europe by the end of 2026, indicating strong potential for market entry.
- Poor Stock Performance: Despite positive clinical data, OSTX shares fell 4.52% to $1.48, trading 2.5% below the 20-day and 12.8% below the 50-day simple moving averages, reflecting market caution regarding future performance.
- Mixed Market Signals: The current RSI of 47.78 suggests neutral territory, while the MACD indicates a potential bullish signal, reflecting complex market sentiment towards OSTX, necessitating investor vigilance.
See More
Ocugen Inc Announces $22.5 Million Stock Offering, Shares Drop 10.48%
- Stock Offering Impact: Ocugen announced a 15 million share offering at $1.50 per share, raising $22.5 million for general corporate purposes and capital spending, leading to investor concerns over dilution and a 10.48% drop in stock price.
- Market Reaction: The offering price below market expectations suggests institutional buyers may have demanded a discount, resetting market expectations for OCGN's near-term value and exacerbating downward pressure on the stock.
- Funding Need Risks: While the financing strengthens Ocugen's balance sheet and supports its gene therapy development, it also highlights the company's reliance on capital markets, increasing perceived risk in an already volatile biotech environment.
- Stock Performance: As of Wednesday, Ocugen shares fell to $1.49, reflecting investor concerns about future profitability, with dilution effects and ongoing cash needs driving significant declines in stock value.
See More
Ocugen (OCGN) Prices 15 Million Share Offering at $1.50, Raising $22.5 Million
- Funding Size: Ocugen announced the pricing of 15 million shares at $1.50 each, raising a total of $22.5 million, which will provide crucial financial support for the company's operations.
- Underwriter Background: The offering is led by RTW Investments and is expected to close around January 22, subject to customary conditions, indicating market confidence in Ocugen.
- Use of Proceeds: Ocugen stated that the net proceeds will be used for general corporate purposes, including capital expenditures, working capital, and general and administrative expenses, thereby enhancing the company's financial flexibility.
- Market Reaction: Following the announcement, Ocugen's stock price rose 8.08% in pre-market trading to $1.535 per share, reflecting investor optimism regarding the company's future prospects.
See More
Ocugen Prices 15 Million Share Offering at $1.50, Raising $22.5 Million
- Offering Size: Ocugen announced the pricing of 15 million shares at $1.50 each, raising a total of $22.5 million, which will be utilized for general corporate purposes and capital expenditures, thereby enhancing the company's financial flexibility.
- Underwriter Participation: The offering is led by RTW Investments with participation from new and existing investors, reflecting market confidence in Ocugen's gene therapy platform and potentially providing funding support for future R&D initiatives.
- Transaction Timeline: The offering is expected to close on or about January 22, 2026, subject to customary closing conditions, providing the company with a swift financing opportunity that could accelerate its research and development efforts.
- Registration Statement Background: This offering is conducted under Ocugen's S-3 registration statement filed on April 18, 2024, demonstrating the company's preparedness in compliance matters, ensuring investors can access relevant information and participate in the investment.
See More
Ocugen Inc Reports 46% Lesion Growth Reduction in Phase 2 Trial, Stock Rallies
- Clinical Trial Results: Ocugen's Phase 2 ArMaDa trial of OCU410 shows a 46% reduction in lesion growth compared to control, indicating significant disease-modifying potential that could position the therapy as an alternative to frequently injected treatments.
- Dose Effect Analysis: The medium dose of OCU410 demonstrated the strongest efficacy with a 54% reduction in lesion size, while the high dose showed a 36% decline, providing robust data support for future treatment options and likely attracting more investor interest.
- Future Development Plans: Ocugen is targeting a Phase 3 trial start in 2026 and plans to file a Biologics License Application in 2028, reflecting the company's confidence in its product pipeline, which may further drive stock price appreciation.
- Strong Market Performance: Ocugen shares are currently priced at $1.76, trading 17.7% above the 20-day simple moving average, indicating strong long-term market performance, with a 149.65% increase over the past 12 months, positioning closer to 52-week highs.
See More
Ocugen Reports Phase 2 Data for OCU410, 46% Lesion Reduction Achieved
- Clinical Trial Results: Preliminary data from Ocugen's Phase 2 trial for OCU410 shows a 46% reduction in lesion growth compared to the control group, indicating the gene therapy's potential efficacy in treating geographic atrophy.
- Dose Effect Analysis: The medium dose achieved a 54% reduction in lesion size, while the high dose showed a 36% reduction, suggesting varying efficacy across doses and potentially offering patients more flexible treatment options.
- Future Plans: Ocugen plans to report full Phase 2 trial data later this quarter and aims to initiate a Phase 3 trial in 2026, further advancing the clinical development of OCU410.
- Market Performance: Despite broader market gains, Ocugen's stock fell 9.08% to $1.71, reflecting a negative market reaction to its clinical data, which may impact future financing and market confidence.
See More
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
- Clinical Trial Progress: OS Therapies' Phase 2b trial of OST-HER2 revealed that immune blood biomarkers in the interferon gamma pathway effectively distinguish long-term from short-term survivors, bolstering their Biologics License Application (BLA) submission.
- Regulatory Approval Path: The company plans to submit its BLA to the FDA by Q2 2026, with regulatory approvals anticipated in the UK, US, and Europe by the end of 2026, indicating strong potential for market entry.
- Poor Stock Performance: Despite positive clinical data, OSTX shares fell 4.52% to $1.48, trading 2.5% below the 20-day and 12.8% below the 50-day simple moving averages, reflecting market caution regarding future performance.
- Mixed Market Signals: The current RSI of 47.78 suggests neutral territory, while the MACD indicates a potential bullish signal, reflecting complex market sentiment towards OSTX, necessitating investor vigilance.
See More
